EpilepsyGTx is a biotechnology company focused on creating adeno-associated viral (AAV) gene therapies for refractory epilepsy and other disorders of neuronal hyperexcitability. Its lead candidate, EPY201, is designed for single, minimally invasive administration directly to the epileptogenic focus and aims to provide durable seizure freedom for patients with focal refractory epilepsy (FRE). The therapy avoids systemic exposure and eliminates the need for brain tissue resection, ablation, or chronic antiseizure medication. The newly secured funding will support first-in-human Phase 1/2a clinical trials to assess EPY201’s safety and efficacy. Beyond this program, the company is building a pipeline of transformative, localized gene therapies addressing severe neurological conditions. EpilepsyGTx has raised $43 million to date, including a $10 million pre-seed and seed round led by the UCL Technology Fund with participation from Zcube, and the recent $33 million Series A. FRE affects approximately 10 million people worldwide, highlighting the significant unmet need EpilepsyGTx seeks to address.

Total raised

$43M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2025